Lysosomal Diseases: From Molecular Features to Precision Medicine

A special issue of Biomolecules (ISSN 2218-273X). This special issue belongs to the section "Molecular Medicine".

Deadline for manuscript submissions: closed (30 November 2023) | Viewed by 2886

Special Issue Editor


E-Mail Website
Guest Editor
Center for Individualized Medicine, Department of Clinical Genomics, Mayo Clinic, Rochester, MN 55905, USA
Interests: lysosomal diseases; individualized medicine; precision medicine; genomics; therapy

Special Issue Information

Dear Colleagues,

Lysosomes are organelles within cells that break down and recycle cellular materials, including proteins, lipids, and carbohydrates. The malfunctioning of lysosomal components such as enzymes or transporters can lead to a buildup of undigested material within lysosomes, resulting in cellular dysfunction and the development of lysosomal diseases (LDs). LDs are a group of over 60 disorders, and while individually rare, as a group, they affect approximately 1 in 5,000 individuals. LDs can manifest as early-onset neurodegenerative diseases, skeletal abnormalities, or visceral dysfunction, and their severity varies widely among individuals even within the same family.

The study of LDs has brought a significant understanding of lysosomal biology and the role of lysosomes in cellular homeostasis. Additionally, LDs are being recognized as an attractive target for precision medicine, as several promising therapies are in development and there is a growing interest in advancing research in this area.

This issue will focus on the latest research findings, innovative therapeutic approaches, and novel insights into the pathophysiology of LDs. The topics covered in this Special Issue will have a broad scope, ranging from basic science to clinical applications, to provide a comprehensive overview of the current state of research in LDs.

We welcome original research articles, short communications and reviews covering a broad range of topics related to LDs, including but not limited to:

  • Genetics and genomics of LDs
  • Molecular and cellular mechanisms of lysosomal dysfunction
  • Emerging therapies for LDs, including gene therapy, enzyme replacement therapy, and small molecule therapeutics
  • Biomarker discovery
  • Animal and cell models
  • Precision Medicine

We also encourage submissions that discuss new technologies, novel therapeutic approaches, and innovative ideas for tackling the challenges of LDs. We hope that this Special Issue will provide a platform for researchers to share their latest findings, encourage collaborations, and stimulate discussions on the future directions of LD research.

Dr. Filippo Vairo
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomolecules is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • lysosomal diseases
  • individualized medicine
  • precision medicine
  • genomics
  • therapy

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Other

23 pages, 1098 KiB  
Systematic Review
Therapeutic Role of Pharmacological Chaperones in Lysosomal Storage Disorders: A Review of the Evidence and Informed Approach to Reclassification
by Ian Keyzor, Simon Shohet, Jeff Castelli, Sheela Sitaraman, Biliana Veleva-Rotse, Jill M. Weimer, Brian Fox, Tobias Willer, Steve Tuske, Louise Crathorne and Klara J. Belzar
Biomolecules 2023, 13(8), 1227; https://doi.org/10.3390/biom13081227 - 7 Aug 2023
Cited by 4 | Viewed by 2586
Abstract
The treatment landscape for lysosomal storage disorders (LSDs) is rapidly evolving. An increase in the number of preclinical and clinical studies in the last decade has demonstrated that pharmacological chaperones are a feasible alternative to enzyme replacement therapy (ERT) for individuals with LSDs. [...] Read more.
The treatment landscape for lysosomal storage disorders (LSDs) is rapidly evolving. An increase in the number of preclinical and clinical studies in the last decade has demonstrated that pharmacological chaperones are a feasible alternative to enzyme replacement therapy (ERT) for individuals with LSDs. A systematic search was performed to retrieve and critically assess the evidence from preclinical and clinical applications of pharmacological chaperones in the treatment of LSDs and to elucidate the mechanisms by which they could be effective in clinical practice. Publications were screened according to the Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) reporting guidelines. Fifty-two articles evaluating 12 small molecules for the treatment of seven LSDs are included in this review. Overall, a substantial amount of preclinical and clinical data support the potential of pharmacological chaperones as treatments for Fabry disease, Gaucher disease, and Pompe disease. Most of the available clinical evidence evaluated migalastat for the treatment of Fabry disease. There was a lack of consistency in the terminology used to describe pharmacological chaperones in the literature. Therefore, the new small molecule chaperone (SMC) classification system is proposed to inform a standardized approach for new, emerging small molecule therapies in LSDs. Full article
(This article belongs to the Special Issue Lysosomal Diseases: From Molecular Features to Precision Medicine)
Show Figures

Figure 1

Back to TopTop